For the first time we demonstrated that rL-RVG acts as a competitive antagonist of α7-nAChR to suppress the migration of gastric cancer cells through inhibiting α7-nAChR-MEK/ERK-EMT. Here, MAP2K7 is linked to gastric cancer.